|
![]() |
|||
|
||||
OverviewRNA Interference: Application to Drug Discovery and Challenges to Pharmaceutical Development provides a general overview of this rapidly emerging field, with a strong emphasis on issues and aspects that are important to a drug development team. The first part covers more general background of RNA interference and its application in drug discovery. In the second part, the book addresses siRNA (small interfering RNA), a pharmaceutically potent form, and its use and delivery in therapeutics along with manufacturing and delivery aspects. Full Product DetailsAuthor: Paul H. Johnson , John J. Rossi (Beckman Research Institute of the City of Hope, Duarte, CA)Publisher: John Wiley & Sons Inc Imprint: John Wiley & Sons Inc Dimensions: Width: 16.00cm , Height: 2.30cm , Length: 23.90cm Weight: 0.590kg ISBN: 9780471771517ISBN 10: 0471771511 Pages: 336 Publication Date: 28 January 2011 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Out of stock ![]() The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available. Table of ContentsReviewsThis is an accessible book that approaches the goal of therapeutic RNAi delivery from a technological viewpoint. Chapter organization and figure presentation allow for interrupted reading without disrupting the flow. Cell and molecular biologists will find both interesting details and practical methods to improve the preclinical applicability of a research project. While therapeutic RNAi is still largely in the development stage, this book promotes a mindset to continue the search for effective delivery strategies. (Doody's, 7 October 2011) """This is an accessible book that approaches the goal of therapeutic RNAi delivery from a technological viewpoint. Chapter organization and figure presentation allow for interrupted reading without disrupting the flow. Cell and molecular biologists will find both interesting details and practical methods to improve the preclinical applicability of a research project. While therapeutic RNAi is still largely in the development stage, this book promotes a mindset to continue the search for effective delivery strategies."" (Doody's, 7 October 2011)" Author InformationPAUL H. JOHNSON, PhD, is a cofounder and Chief Scientific Officer at PhaseRx, Inc. He is the author of numerous scientific papers and patents, and was the recipient of the 2007 Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery. Tab Content 6Author Website:Countries AvailableAll regions |